European biotech firms look for ways to bring cancer research to patients faster
In describing a new roundtable podcast episode, the news site EU-Startups lists four European biotech themes in cancer care. They cover moving science into treatment, using microalgae to make biologic drugs, making cell therapy scalable, and the role of AI in chemistry.
EU-Startups, a news site covering European startups, has published a special roundtable episode of The EU-Startups Podcast on how the European biotechnology sector is changing cancer care. The post sets out the main talking points, which concern cancer treatment and new approaches to making medicines.
Main themes
First, the discussion says that bridging the gap between scientific breakthroughs and real-world cancer care remains one of Europe's biggest challenges.
Second, it notes that sustainable biomanufacturing based on microalgae could become a serious alternative for producing antibodies and other biologics.
Third, it stresses that moving cell therapy from highly personalised treatments to scalable, "off-the-shelf" solutions is key to reaching far more patients.
The fourth point concerns artificial intelligence and generative chemistry, but the source excerpt is cut off at that spot, so the full wording is not available.
The published text is only a short summary of the episode, so it does not name the participants or their companies or give further detail on their arguments.
